IP Library › Granted Patent US 12,383,542
Granted Patent B2
US 12,383,542 · App. 15/986,536 · Granted Aug 12, 2025

Methods of treating ovarian cancer

Inventors: Mary Lynne Hedley (Waltham, MA); Robert Martell (Waltham, MA)
Assignee: Tesaro, Inc.
A61K31/454A61K31/4745A61P35/00A61K9/48C12Q1/6886C12Q2600/106C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,383,542
App. No.
15/986,536
Granted
Aug 12, 2025
Kind
B2
Abstract

The present invention provides methods of administering a PARP inhibitor to a cancer patient.

Claims (28)

1. A method of treating a patient diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, comprising

administering daily to said patient an oral dose of niraparib equivalent to 200 mg or 300 mg of niraparib free base,

wherein the patient has undergone at least one cycle of platinum-based chemotherapy; and

wherein the patient carries no germline or somatic mutation in BRCA1 or BRCA2 genes and the cancer has no homologous recombination deficiency.

2. The method of claim 1 , wherein the ovarian cancer, fallopian tube cancer, or primary peritoneal cancer is platinum sensitive.

3. The method of claim 1 , wherein the patient has undergone at least two cycles of platinum-based chemotherapy.

4. The method of claim 3 , wherein the patient has a complete response to the platinum-based chemotherapy.

5. The method of claim 3 , wherein the patient has a partial response to the platinum-based chemotherapy.

6. The method of claim 3 , wherein the administration of niraparib is commenced within 8 weeks of the end of the last cycle of platinum-based chemotherapy.

7. The method of claim 1 , comprising administering the niraparib in continuous 28-day cycles.

8. The method of claim 1 , wherein the niraparib is administered daily for a period of 6.9 months, and wherein administration is continued until disease progression occurs.

9. The method of claim 1 , comprising administering daily to said patient an oral dose of niraparib tosylate monohydrate.

10. The method of claim 9 , comprising administering daily to said patient an oral dose of niraparib tosylate monohydrate equivalent to 200 mg of niraparib free base.

11. The method of claim 9 , comprising administering daily to said patient an oral dose of niraparib tosylate monohydrate equivalent to 300 mg of niraparib free base.

12. A method of treating a patient diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, consisting of

administering daily to said patient an oral dose of niraparib equivalent to 200 mg or 300 mg of niraparib free base,

wherein the patient has undergone at least one cycle of platinum-based chemotherapy; and

wherein the patient carries no germline or somatic mutation in BRCA1 or BRCA2 genes and the cancer has no homologous recombination deficiency.

13. The method of claim 12 , wherein the ovarian cancer, fallopian tube cancer, or primary peritoneal cancer is platinum sensitive.

14. The method of claim 12 , wherein the patient has undergone at least two cycles of platinum-based chemotherapy.

15. The method of claim 14 , wherein the patient has a complete response to the platinum-based chemotherapy.

16. The method of claim 14 , wherein the patient has a partial response to the platinum-based chemotherapy.

17. The method of claim 14 , wherein the administration of niraparib is commenced within 8 weeks of the end of the last cycle of platinum-based chemotherapy.

18. The method of claim 12 , comprising administering the niraparib in continuous 28-day cycles.

19. The method of claim 12 , wherein the niraparib is administered daily for a period of 6.9 months, and wherein administration is continued until disease progression occurs.

20. The method of claim 12 , comprising administering daily to said patient an oral dose of niraparib tosylate monohydrate.

21. The method of claim 20 , comprising administering daily to said patient an oral dose of niraparib tosylate monohydrate equivalent to 200 mg of niraparib free base.

22. The method of claim 20 , comprising administering daily to said patient an oral dose of niraparib tosylate monohydrate equivalent to 300 mg of niraparib free base.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2018
From: HEDLEY, MARY LYNNE; MARTELL, ROBERT
To: TESARO, INC.
Reel/Frame 046622/0245 →
Continuity (5)
Continuation PCTUS2017040039 · Jun 29, 2017
Provisional Application 62470141 · Mar 10, 2017
Provisional Application 62402427 · Sep 30, 2016
Provisional Application 62356461 · Jun 29, 2016
Related Publication 20180311224A1 · Nov 1, 2018
References Cited (400)
US 8071623B2 · Jones et al. · 2011 [cited by applicant]
US 8436185B2 · Foley et al. · 2013 [cited by applicant]
US 9580407B2 · Chung et al. · 2017 [cited by applicant]
US 9738915B2 · Bulger et al. · 2017 [cited by applicant]
US 20090123419A1 · Sherman et al. · 2009 [cited by applicant]
US 20090275619A1 · Boueres et al. · 2009 [cited by applicant]
US 20100009930A1 · Sherman et al. · 2010 [cited by applicant]
US 20100286157A1 · Quigley et al. · 2010 [cited by applicant]
US 20100286203A1 · Foley et al. · 2010 [cited by applicant]
US 20110118217A1 · Gudmundsson et al. · 2011 [cited by applicant]
US 20110201657A1 · Boueres et al. · 2011 [cited by applicant]
US 20120207856A1 · Ajay et al. · 2012 [cited by applicant]
US 20120214998A1 · Bierlmaier et al. · 2012 [cited by applicant]
US 20130310424A1 · Surber · 2013 [cited by applicant]
US 20140363521A1 · Abkevich · 2014 [cited by examiner]
US 20150110869A1 · Philip et al. · 2015 [cited by applicant]
US 20150344968A1 · Johnson · 2015 [cited by applicant]
US 20160160294A1 · Wilcoxen et al. · 2016 [cited by applicant]
US 20170000885A1 · Rhee et al. · 2017 [cited by applicant]
US 20170029428A1 · Blatter et al. · 2017 [cited by applicant]
US 20170137403A1 · Chung et al. · 2017 [cited by applicant]
US 20170335359A1 · Bulger et al. · 2017 [cited by applicant]
US 20190060285A1 · Proia · 2019 [cited by examiner]
US 20210106574A1 · Feng et al. · 2021 [cited by applicant]
US 20220175751A1 · Hedley et al. · 2022 [cited by applicant]
US 20220175752A1 · Hedley et al. · 2022 [cited by applicant]
CA 2893280 · 2014 [cited by applicant]
CN 105384695 · 2016 [cited by applicant]
CN 105960415 · 2016 [cited by applicant]
CN 106132439 · 2016 [cited by applicant]
CN 106432055 · 2017 [cited by applicant]
CN 106496187 · 2017 [cited by applicant]
JP 2011506252 · 2011 [cited by applicant]
JP 2011509252 · 2011 [cited by applicant]
JP 2011509253 · 2011 [cited by applicant]
JP 2017504623 · 2017 [cited by applicant]
JP 2017509631 · 2017 [cited by applicant]
JP 2017527799 · 2017 [cited by applicant]
WO WO2007113596 · 2007 [cited by applicant]
WO WO2008084261 · 2008 [cited by applicant]
WO WO2009087381 · 2009 [cited by applicant]
WO WO2011058367 · 2011 [cited by applicant]
WO WO2011153383 · 2011 [cited by applicant]
WO WO2011160063 · 2011 [cited by applicant]
WO WO2012027224 · 2012 [cited by applicant]
WO WO2013182645 · 2013 [cited by applicant]
WO WO2014052550A1 · 2014 [cited by applicant]
WO WO2014088983 · 2014 [cited by applicant]
WO WO2014088984 · 2014 [cited by applicant]
WO WO2014138101 · 2014 [cited by applicant]
WO WO2014179664 · 2014 [cited by applicant]
WO WO2015108986A1 · 2015 [cited by applicant]
WO WO2015119930 · 2015 [cited by applicant]
WO WO2015153514 · 2015 [cited by applicant]
WO WO2015184145 · 2015 [cited by applicant]
WO WO2016094391 · 2016 [cited by applicant]
WO WO2019123207 · 2016 [cited by applicant]
WO WO2016200835 · 2016 [cited by applicant]
WO WO2017075091 · 2017 [cited by applicant]
WO WO2017139694 · 2017 [cited by applicant]
WO WO2018005818 · 2018 [cited by applicant]
WO WO2018023017 · 2018 [cited by applicant]
WO WO2018183349 · 2018 [cited by applicant]
WO WO2018183354 · 2018 [cited by applicant]
WO WO2018200517 · 2018 [cited by applicant]
WO WO2018201096 · 2018 [cited by applicant]
WO WO2019005762 · 2019 [cited by applicant]
WO WO2019067634 · 2019 [cited by applicant]
WO WO2019133697 · 2019 [cited by applicant]
WO WO2021011609 · 2021 [cited by applicant]
Over Sandhu et a., “The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial,” Lancet Oncol 2013; 14:882-92. [cited by examiner]
Jones et al., “Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination,” Journal of Medicinal Chemistry, Mar. 11, 2015. [cited by examiner]
Konstantinopolous et al., “Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer,” Cancer Discov. Nov. 2015; 5(11):1137-1154. [cited by examiner]
Michie et al., “Final Result of the phase I trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation ca… [cited by examiner]
Telli et al., Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer, Clin Cancer Res (published online Mar. 8, 2… [cited by examiner]
AlHilli MM et al., “In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma: Single agent and combination response”, Mol Cancer Ther. [cited by applicant]
Audeh MW, “Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition”, Pharmgenomics Pers Med, Oct. 2014, 7: 307-316. [cited by applicant]
Bridges KA et al., “Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells”, [cited by applicant]
Carey JPW et al., “Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer”, [cited by applicant]
Chang H et al., “Enhanced Anti-Tumor Effects of Selinexor and Niraparib in Preclinical Models of Ovarian Cancer”, (Abstract 5826). Presented at AACR 2018 (Poster). [cited by applicant]
Deas O et al., “Preclinical evaluation of the PARP inhibitor niraparib and cytotoxic chemotherapy alone or in combination in a panel of 25 triple-negative breast cancer PDX models: relevance of BRCA mutations, HRD statu… [cited by applicant]
Del Campo JM et al., “The Successful Phase 3 Niraparib ENGOT-OV16/NOVA Trial Included a Substantial Number of Patients with Platinum Resistant Ovarian Cancer”, ASCO 2017 (Poster). [cited by applicant]
Engert F et al., “PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway”, [cited by applicant]
Fabbro M et al., “Safety and efficacy of niraparib in elderly patients (Pts) with recurrent ovarian cancer (OC)”, Presented at ESMO; Sep. 8-12, 2017; Madrid, Spain. 934PD. [cited by applicant]
Fisher M et al., “Cost-effectiveness of niraparib versus routine surveillance, olaparib and rucaparib for the maintenance treatment of adult patients with ovarian cancer in the United States”, Accepted at ASCO 2018 (Pos… [cited by applicant]
Genther-Williams SM et al., “Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status”, [cited by applicant]
González MA et al., “A randomized, double-blind phase 3 trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy”, ASCO 2016. (Poste… [cited by applicant]
González MA et al., “A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy”, Presented at E… [cited by applicant]
González MA et al., “A randomized, double-blind phase 3 trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy”, SGO 2017 (Poster). [cited by applicant]
González MA et al., “The ENGOT-OV26/PRIMA phase 3 trial: Niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy”, ESGO 2017 (e-poster). [cited by applicant]
Guy J et al., “Cost-effectiveness of niraparib versus routine surveillance and olaparib for the maintenance treatment of adult patients with ovarian cancer in the United States”, Accepted at ISPOR 2018 (Poster). [cited by applicant]
Haluska P et al., “Homologous recombination deficiency (HRD) score and niraparib efficacy in high grade ovarian cancer”, Emergency Nurses Association 2014. (Oral Presentation). [cited by applicant]
Harrow B et al., “Disease Burden During the ‘Watchful Waiting’ Period in Women with Recurrent Ovarian Cancer in Germany”, EU ISPOR 2017 (Poster). [cited by applicant]
Harrow B et al., “Disease burden during the “watchful waiting” period in patients with recurrent ovarian cancer”, Presented at ESMO; Sep. 8-12, 2017; Madrid, Spain. 962P. [cited by applicant]
Hopkins TA et al., “Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors”, [cited by applicant]
Jones P et al., “Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors”, [cited by applicant]
Jones P et al., “Niraparib: A poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination”, [cited by applicant]
Konstantinopoulos PA et al., “Dose-finding combination study of niraparib and pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant epithelial ovarian cance… [cited by applicant]
Konstantinopoulos P et al., “Phase 1/2 study of niraparib plus pembrolizumab in patients with triple-negative breast cancer or recurrent ovarian cancer (Keynote-162)”, ASCO 2016. (Poster). [cited by applicant]
Konstantinopoulos PA et al., “TOPACIO: Preliminary activity and safety in patients with platinum-resistant ovarian cancer in a phase 1/2 study of niraparib in combination with pembrolizumab”, SGO 2018 (Oral). [cited by applicant]
Kurzrock R et al., “A phase I study of niraparib in combination with temozolomide (TMZ) in patients with advanced cancer”, ASCO 2014. (Poster). [cited by applicant]
Ledermann J et al., Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). BGCS 2017 (Poster, encore publication). [cited by applicant]
Lodhia KA et al., “Characterization of 148 Ovarian Cancer tumografts (Avatars) using BROCA-HR deep sequencing”, TAT 2015. (Poster). [cited by applicant]
Lord R et al., “Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase 3 trial”, SGO 2018 (Oral). [cited by applicant]
Mahner S et al., “ENGOT-OV16/NOVA: Results of secondary efficacy endpoints of niraparib maintenance therapy in ovarian cancer”, SGO 2017 (Oral presentation). [cited by applicant]
Matulonis UA et al., “A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial)”, ASCO 2014. (Poster). [cited by applicant]
Matulonis U et al., “Engot-ov16/nova: A maintenance study with niraparib versus placebo in patients with platinum-sensitive ovarian cancer”, [abstract No. IGCS-0912]. Int J Gynecol Cancer. 2016; 26 (Suppl 3): 19-20. IGC… [cited by applicant]
Matulonis UA et al., “Long Term Benefit of Niraparib Treatment of Recurrent Ovarian Cancer (OC)”, ASCO 2017 (Poster). [cited by applicant]
Michie CO et al., “Final results of the phase I trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutatio… [cited by applicant]
Mikule K et al., “A mouse avatar tumor maintenance study identified a subset of SCLC patient-derived tumor xenograft models sensitive to the PARP inhibitor niraparib”, EORTC-NCI-AACR 2015. [cited by applicant]
Mikule K et al., “A preclinical evaluation of niraparib efficacy as monotherapy, maintenance and after olaparib treatment (PARP inhibitor after PARP inhibitor) in patient-derived ovarian xenograft tumor models”, ECCO 20… [cited by applicant]
Mikule K et al., “The PARP inhibitor, niraparib, crosses the blood brain barrier in rodents and is efficacious in a BRCA2-mutant intracranial tumor model”, EORTC-NCI-AACR 2015. (Poster). [cited by applicant]
Mirza MR et al., “A phase 1 study to evaluate the safety and tolerability of bevacizumab-niraparib combination therapy and determine the recommended phase 2 dose (RP2D) in women with platinum-sensitive epithelial ovaria… [cited by applicant]
Mirza MR et al., “Efficacy of Niraparib on Progression-free Survival (PFS) in Patients (Pts) with Recurrent Ovarian Cancer (OC) with Partial Response to the Last Platinum-based Chemotherapy” ASCO 2017. (Poster). [cited by applicant]
Mirza MR et al., “ENGOT-OV16/NSGO/NOVA: A phase 3 randomized double-blind trial of maintenance with parp-inhibitor niraparib vs. placebo in patients with platinum-sensitive ovarian cancer”, ESMO 2014. (Poster). [cited by applicant]
Mirza M et al., “Engot-OV16/NOVA: A phase 3 randomized double-blind trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer. IGCS 2014”, (Oral Presentation). [cited by applicant]
Mirza MR et al., “Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer,” [cited by applicant]
Mirza MR et al., “Niraparib alone versus niraparib-bevacizumab combination versus bevacizumab followed by niraparib in women with platinum-sensitive ovarian cancer”, ASCO 2015. (Poster). [cited by applicant]
Mirza MR et al., “Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial)”, ESMO 2016 (Oral Presentation). [cited by applicant]
Moore K et al., “Food effect sub study of a phase 3 randomized double-blind trial of maintenance with niraparib, a poly(adp)ribose polymerase (PARP) inhibitor in platinum-sensitive ovarian cancer patients”, ESGO 2015. (… [cited by applicant]
Moore KN et al., “Food effect substudy of a phase 3 randomized double-blind trial of maintenance with niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor versus placebo in patients with platinum sensitive … [cited by applicant]
Moore KN et al., “Phase 2, open-label study of niraparib in women with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer after ≥3 previous chemotherapy regimens”, ASCO… [cited by applicant]
Moore K et al., “Safety and efficacy of niraparib in patients with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer (QUADRA)”, [abstract No. IGCS-0883]. Int J Gyneco… [cited by applicant]
Moore K et al., “The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer”, [cited by applicant]
Mueller S et al., “Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma”, [cited by applicant]
Murai J et al., “Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors” [cited by applicant]
Neeser K et al., “Budget impact of niraparib as maintenance treatment for Medicare patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based … [cited by applicant]
Neeser K et al., “The cost consequences of maintenance therapies for patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy”,… [cited by applicant]
Oza A et al., “Quality of live in recurrent ovarian cancer patients treated with niraparib: Results from the ENGOT-OV16/NOVA Trial”, Presented at ESMO; Sep. 8-12, 2017; Madrid, Spain. 930O. [cited by applicant]
Parpos P et al., “Comparison of dose intensity in clinical trial and real world settings for niraparib”, Accepted at ISPOR 2018 (Poster). [cited by applicant]
Postel-Vinay S et al., “A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer”, [cited by applicant]
Sambade MJ et al., “Efficacy and pharmacokinetics of niraparib in BRCA-mutant and wild-type intracranial triple negative breast cancer murine models”, (Abstract: 2813). Presented at AACR 2018 (Poster). [cited by applicant]
Sandhu SK et al., “The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial”, [cited by applicant]
Schelman WR et al., “First in Human Trial of a Poly(ADP-ribose) Polymerase (PARP) Inhibitor MK-4827 in Advanced Cancer Patients with Antitumor Activity in BRCA-Deficient Tumors and Sporadic Ovarian Cancers”, ASCO 2011. … [cited by applicant]
Shen Y et al., “Trapping Poly(ADP-Ribose) Polymerase”, [cited by applicant]
Sun K et al., “A comparative pharmacokinetic-pharmacodynamic-treatment study of PARP inhibitors demonstrates favorable properties for niraparib activity in pre-clinical tumor models”, AACR/NCI/EORTC Oct. 2017(Poster). [cited by applicant]
Timms K et al., “DNA repair deficiencies in ovarian cancer: Genomic analysis of high grade serous ovarian tumors from the NOVA study”, ECC/ESMO 2015. (Poster). [cited by applicant]
Tryfonidis K et al., “A phase III randomized trial of niraparib versus physician's choice in previously-treated, HER2 negative, germline-BRCA mutated breast cancer patients: An EORTC-BIG intergroup study”, ASCO 2014. (P… [cited by applicant]
Tryfonidis K et al., “A phase III randomized trial of niraparib versus physician's choice in previously treated, HER2 negative, germline-BRCA mutated breast cancer patients: An EORTC-BIG intergroup study”, SABCS 2015. (… [cited by applicant]
Van Andel L et al., “Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients”, Cancer Chemother Pharmacol. 2017. [cited by applicant]
Van Andel L et al., “Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer”, Invest New Drugs. 2017. [cited by applicant]
Van Andel L et al., “Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine”, [cited by applicant]
Vinayak S et al., “TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial”, Accepted at ASCO 2018 (Oral). [cited by applicant]
Wang S et al., “Elevation of immune cell infiltration and interferon-stimulated gene expression is associated with niraparib treatment in murine syngeneic tumor models”, AACR/NCI/EORTC Oct. 2017 (Poster). [cited by applicant]
Wang S et al., “Evaluation of niraparib in combination with anti-PD-1/anti-PD-L1 in preclinical models”, 3rd DNA replication/Repair Structures and Cancer Conference. [cited by applicant]
Wang S et al., “Evaluation of niraparib in combination with anti-pd-1/anti-pd-l1 in preclinical models”, (Abstract 1724). Presented at AACR 2018. [cited by applicant]
Wang L et al., “MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation”, [cited by applicant]
Wang Y et al., “Niraparib, a selective PARP 1/2 inhibitor, is efficacious in pre-clinical models of small-cell lung cancer”, EORTC-NCI-AACR 2014. (Poster). [cited by applicant]
Wang J et al., “Preclinical Anti-tumor Activity of Niraparib and Its Combination with Anti-PD-1 Therapy”, PARP2017 (oral presentation). [cited by applicant]
Wang S et al., “Preclinical evaluation of niraparib in combination with anti-PD1/anti-PDL1 in mouse-derived syngeneic transplant models”, AACR I&I Oct. 2017, Abstract B16 (Poster). [cited by applicant]
Wang J et al., “The exposure-response relationship of niraparib in patients (pts) with gBRCAmut and non-gBRCAmut: results from the Phase 3 ENGOT-OV16/NOVA Trial”, Presented at ESMO; Sep. 8-12, 2017; Madrid, Spain. 933PD. [cited by applicant]
Wang Y et al., “The PARP inhibitor niraparib demonstrates robust activity in a subset of patient-derived triple-negative breast cancer xenograft models”, AACR 2014. (Poster). [cited by applicant]
Wang Y et al., “The PARP inhibitor niraparib demonstrates activity in patient-derived triple-negative breast cancer xenograft models with high homologous recombination deficiency (HRD) score”, SABCS 2014. (Poster). [cited by applicant]
Wilcoxen KM et al, “Homologous recombination deficiency (HRD) score enriches for niraparib sensitive high grade ovarian tumors” ASCO 2015. (Poster). [cited by applicant]
Zhang Z-Y et al., “Biotransformation and disposition of niraparib, a selective human PARP-1 and PARP-2 antagonist, in vitro”, ISSX 2015. (Poster). [cited by applicant]
Zhang Z-Y et al., “Characterization of absorption, metabolism, and elimination of niraparib, an investigational poly (ADP-ribose) polymerase inhibitor, in cancer patients”, EACPT 2017 (oral presentation). [cited by applicant]
Zhang Z-Y et al., “Disposition and Biotransformation of Niraparib, a Selective Human PARP-1 and PARP-2 Antagonist, in Vivo”, ISSX 2015. (Poster). [cited by applicant]
Zhang ZY et al., “Modeling and impact of organ function on the population pharmacokinetics (PK) of niraparib, a selective poly (ADP-ribose) polymerase (PARP)-1 and -2 inhibitor”, Presented at ESMO; Sep. 8-12, 2017; Madr… [cited by applicant]
Zhang ZY et al., “Pharmacokinetics of the poly (ADP-ribose) polymerase inhibitor (PARPi) niraparib”, World Congress on Pharmacology 2017 (oral presentation). [cited by applicant]
Essel et al., “Niraparib for the treatment of ovarian cancer”, Expert Review of Anticancer Therapy, 18(8): 727-733 (2018). [cited by applicant]
Kang et al., “Regulation of DNA repair in the absence of classical non-homologous end joining”, DNA Repair, 68: 34-40 (2018). [cited by applicant]
Vasconcelos et al., “Meta-analysis on the PARP-inhibitor olaparib reveals therapeutic efficacy in ovarian cancer independent of BRCA1/2 mutation status”, Advances in Modern Oncology Research, 2(1): 91-96 (2016). [cited by applicant]
Moore, “The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities”, Gynecologic Oncology, 149(1): 214-220 (2018). [cited by applicant]
Caruso, “Niraparib in ovarian cancer: results to date and clinical potential”, Therapeutic Advances in Medical Oncology, 9(9): 579-588 (2017). [cited by applicant]
Kanjanapan et al., “Niraparib for the treatment of ovarian cancer”, Expert Opinion on Pharmacotherapy, 18(6): 631-640 (2017). [cited by applicant]
Farmer et al., “Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy”, Nature, 434: 917-921 (2005). [cited by applicant]
Hamilton et al., “Emotional Distress Following Genetic Testing for Hereditary Breast and Ovarian Cancer: A Meta-Analytic Review”, Health Psychol., 28(4): 510-518 (2009). [cited by applicant]
Listøl et al., “Anxiety and depression symptoms among women attending group-based patient education courses for hereditary breast and ovarian cancer”, Hereditary Cancer in Clinical Practice, 15:2, 1-9 (2017). [cited by applicant]
Ramus, “The Contribution of BRCA1 and BRCA2 to Ovarian Cancer”, Mol Oncol., 3(2): 138-150 (2009). [cited by applicant]
Gelmon et al., “Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study”, Lancet Oncol.… [cited by applicant]
Ledermann et al., “Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer”, N. Eng. J. Med., 366(15): 1382-1392 (2012). [cited by applicant]
Moore et al., “Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer”, N. Eng. J. Med. 1-11 (2018). [cited by applicant]
Moore et al., “Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer”, N. Eng. J. Med. Supplementary Appendix (2018). [cited by applicant]
“Niraparib Slows Ovarian Cancer Progression”, Cancer Discovery., 6(12): OF2, (2016). [cited by applicant]
Kaufman et al., “Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation”, Journal of Clinical Oncology, 33(3): 244-250 (2015). [cited by applicant]
George et al., “Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer”, Nature Reviews Clinical Oncology, 14(5): 284-296 (2017). [cited by applicant]
Bryant et al., “Synthetic Lethality with Homologous Recombination Repair Defects”, PARP Inhibitors for Cancer Therapy (Cancer Drug Discovery and Development), Chapter 13, 315-344 (2015). [cited by applicant]
Moore et al., “SOLO1: Phase III trial of maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients with advanced ovarian cancer and a BRCA1/2 mutation”, slides presented at European Society … [cited by applicant]
Davies et al., “Top 40 Drugs in the Pipeline”, A Supplement to C&EN, 1-33, (2016). [cited by applicant]
https://www.fool.com/investing/2016/06/29/shares-of-tesaro-inc-have-more-than-doubled-today.aspx. [cited by applicant]
https://www.streetinsider.com/Analyst+Comments/TESARO+%28TSRO%29+Phase +3+Niraparib+Results+a+Grand+Slam+-+Mizuho/11784621.htm. [cited by applicant]
https://www.statnews.com/2016/06/30/ovarian-cancer-new-drugs/. [cited by applicant]
https://www.medscape.com/viewarticle/870021. [cited by applicant]
https://www.onclive.com/web-exclusives/fda-approves-niraparib-for-ovarian-cancer. [cited by applicant]
https://www.esmo.org/Conferences/Past-Conferences/ESMO-2016-Congress/Press-Media/Niraparib-Significantly-Improves-Outcome-of-Ovarian-Cancer-Patients-in-Landmark-Trial. [cited by applicant]
http://www.ascopost.com/issues/november-25-2016/breakthrough-in-recurrent-ovarian-cancer-niraparib-extends-progression-free-survival-in-platinum-sensitive-disease/. [cited by applicant]
https://www.mdedge.com/oncologypractice/article/115513/gynecologic-cancer/parp-inhibitor-prolongs-pfs-ovarian-cancer. [cited by applicant]
http://www.pmlive.com/pharma_news/tesaros_niraparib_threatens_lynparza_after_acing_ovarian_cancer_trial_1160149. [cited by applicant]
Lynparza® Label Dec. 2014. [cited by applicant]
Rubraca® Label Dec. 2016. [cited by applicant]
Zejula® Label Mar. 2017. [cited by applicant]
Lynparza® Label Aug. 2017. [cited by applicant]
Rubraca® Label Apr. 2018. [cited by applicant]
Ledermann et al., “Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”, Annals of Oncology, 24 (Supplement 6), vi24-vi32 (2013). [cited by applicant]
FDA Briefing Document: Oncologic Drugs Advisory Committee Meeting, Jun. 25, 2014. [cited by applicant]
Ledermann et al., “eUpdate Ovarian Cancer Treatment Recommendations”, European Society for Oncology (2016). [cited by applicant]
http://ir.tesarobio.com/news-releases/news-release-details/tesaros-niraparib-significantly-improved-progression-free. [cited by applicant]
Zejula® Marketing materials (2018). [cited by applicant]
Mikule, K. “Targeting Cancers with DNA Repair: Beyond BRCA,” presented at Boston Oncology Drug Discovery Symposium (2018). [cited by applicant]
Zejula® marketing materials, “The NOVA Trial Independently Tested the Benefit of ZEJULA in gBRCAmut and Non-gBRCAmut Populations”, (2017). [cited by applicant]
https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-updates-on-olaparib-and-TC-5214-development-programmes-20122010.html#. [cited by applicant]
https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-olaparib-clinical-programme-brca-mutated-ovarian-cancer-treatment-04092013.html#. [cited by applicant]
Lederman et al., “Olaparib maintenance therapy in patients with platinumsensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial”, Lancet Onc… [cited by applicant]
Umscheid et al., “Key Concepts of Clinical Trials: A Narrative Review”, Postgraduate Medicine, 123(5): 194-204 (2011). [cited by applicant]
Mahipal et al., “Risks and Benefits of Phase 1 Clinical Trial Participation”, Cancer Control, 21(3): 193-199 (2014). [cited by applicant]
Mandrekar et al., “Design of clinical trials for biomarker research in oncology”, Clin. Invest., 1(12): 1627-1636 (2011). [cited by applicant]
Yap et al., “Poly(ADP-Ribose) Polymerase (PARP) Inhibitors: Exploiting a Synthetic Lethal Strategy in the Clinic”, CA Cancer J Clin, 61(1):31-49 (2011). [cited by applicant]
Lin et al., “Reinventing clinical trials: a review of innovative biomarker trial designs in cancer therapies”, British Medical Bulletin, 114(1):17-27 (2015). [cited by applicant]
Cook et al., “Early phase clinical trials to identify optimal dosing and safety”, Molecular Oncology, 9(5): 997-1007 (2015). [cited by applicant]
http://www.pharmafile.com/news/188925/fda-rejects-olaparib. [cited by applicant]
https://blogs.shu.edu/cancer/2014/06/26/parp-inhibitor-rejected-by-fda-advisory-committee/. [cited by applicant]
http://www.egdutton2.com/research/progress/snapshots/ovarian.html. [cited by applicant]
http://www.egdutton2.com/types/ovarian/hp/ovarian-epithelial-treatment-pdq.html. [cited by applicant]
https://ocrahope.org/patients/about-ovarian-cancer/recurrence/. [cited by applicant]
https://www.astrazeneca-us.com/media/press-releases/2014/lynparza-approved-by-the-us-fda-20141219.html#! [cited by applicant]
https://ir.clovisoncology.com/investors-and-news/news-releases/press-release-details/2016/Clovis-Oncology-Announces-FDA-Accelerated-Approval-of-RUBRACA-rucaparib-for-the-Monotherapy-Treatment-of-Advanced-Ovarian-Cancer-… [cited by applicant]
http://ir.tesarobio.com/news-releases/news-release-details/tesaro-announces-us-fda-approval-zejulatm-niraparib-women. [cited by applicant]
http://www.ascopost.com/issues/january-25-2017/parp-inhibitor-niraparib-yields-unprecedented-results-in-ovarian-cancer-in-phase-iii-trial/?utm_source=TrendMD&utm_medium=cpc&utm_campaign=The_ASCO_Post_TrendMD_0. [cited by applicant]
https://seekingalpha.com/article/4011207-tesaro-enjoys-ta-dah-moment. [cited by applicant]
http://ir.tesarobio.com/news-releases/news-release-details/tesaro-and-myriad-announce-companion-diagnostics-collaboration. [cited by applicant]
Berek et al., “Safety and dose modification for patients receiving niraparib,” [cited by applicant]
Chase et al.; “Profile of Olaparib in the treatment of advanced ovarian cancer,” Int J Women's Health., 6(8): 125-129, (2016). [cited by applicant]
https://www.astrazeneca.com/media-centre/press-releases/2018/solo-1-phase-III-trial-demonstrates-lynparza-maintenance-therapy-cut-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advan… [cited by applicant]
https://www.astrazeneca.com/media-centre/press-releases/2016/lynparza-phase-iii-solo-2-trial-shows-significant-progression-free-survival-benefit-261020161.html#. [cited by applicant]
https://myriad.com/patients-families/genetic-testing-101/genetic-testing-faqs/. [cited by applicant]
http://www.ascopost.com/issues/november-25-2016/expert-point-of-view-sandro-pignata-md/. [cited by applicant]
https://clinicaltrials.gov/ct2/show/NCT02655016?term=niraparib&recrs=d&rank=7. [cited by applicant]
National Academies of Sciences, Engineering, and Medicine. “Ovarian cancers: Evolving paradigms in research and care” Washington, DC: The National Academies Press (2016). [cited by applicant]
Morin et al., Ovarian Cancer. In: Schwab M. (eds) Encyclopedia of Cancer. Springer, Berlin, Heidelberg. pp. 2671-2674 (2011). [cited by applicant]
Ex Parte Liu, Appeal 2018-000869, 2018 WL 3492109 (Jul. 3, 2018). [cited by applicant]
Ex Parte Pu, Appeal 2017-003775, 2018 WL 3425476 at (Jun. 25, 2018). [cited by applicant]
https://xconomy.com/boston/2017/03/27/tesaros-ovarian-cancer-drug-gets-fda-nod-no-diagnostic-needed/. [cited by applicant]
Fong et al., “Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers”, N Engl J Med. 2009; 361(2): 123-134. [cited by applicant]
Audeh et al., “Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial”, Lancet. 2010; 376(9737): 245-251. [cited by applicant]
Kummar et al., “A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas”, Clin Cancer Res. 2012; 18(6): 1726-1734. [cited by applicant]
Turner et al., “Biomarkers of PARP Inhibitor Sensitivity”, Breast Cancer Res Treat. 2011; 127(1): 283-286. [cited by applicant]
Wooster et al., Identification of the breast cancer susceptibility gene BRCA2, Nature. 1995; 378(6559): 789-792. [cited by applicant]
Chen et al., “BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway”, Cancer Res. 1999; 59(7 Suppl): 1752s-1756s. [cited by applicant]
Turner et al., “Hallmarks of ‘BRCAness’ in sporadic cancers”, Nat Rev Cancer. 2004;4(10): 814-819. [cited by applicant]
Kang et al., “A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy”, J Natl Cancer Inst. 2012; 104(9): 670-681. [cited by applicant]
Konstantinopoulos et al., “Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer”, J Clin Oncol. 2010; 28(22): 3555-3561. [cited by applicant]
Stefansson et al., “Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes”, Breast Cancer Res. 2009; 11(4): R47. [cited by applicant]
Siegel et al., “Cancer statistics, 2014”, CA Cancer J Clin. 2014; 64(1): 9-29. [cited by applicant]
United States Court of Appeals for the Federal Circuit, Novartis Pharmaceuticals Corporation, Novartis AG, Plaintiffs- [cited by applicant]
Smietana, K et al., “From the Analyst's Couch—Trends in Clinical Success Rates”, Nature Review | Drug Discovery, pp. 1-2, May 20, 2016. [cited by applicant]
American Cancer Society, “Ovarian Cancer, 2016”, http://www.cancer.org/cancer/ovariancancer/index, Accessed May 13, 2019. [cited by applicant]
Vine et al., “Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls”, Gynecol Oncol. 2003; 90(1): 75-82. [cited by applicant]
Goff et al., “Frequency of symptoms of ovarian cancer in women presenting to primary care clinics”, JAMA. 2004; 291(22): 2705-2712. [cited by applicant]
Havrilesky et al., “Quality of life in ICON7: need for patients' perspectives”, Lancet Oncol. 2013; 14(3): 183-185. [cited by applicant]
Company B-MS, Taxol® (paclitaxel) Injection Package Insert. 2011; http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s0491bl.pdf, Accessed May 17, 2016. [cited by applicant]
Birrer, “Ovarian cancer: targeting the untargetable”, Am Soc Clin Oncol Educ Book. 2014: 13-15. [cited by applicant]
Ferrel et al., “Psychological well being and quality of life in ovarian cancer survivors”, Cancer. 2003; 98(5): 1061-1071. [cited by applicant]
Reb, “Transforming the death sentence: elements of hope in women with advanced ovarian cancer”, Oncol Nurs Forum. 2007; 34(6): E70-81. [cited by applicant]
Havrilesky et al., “Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment”, Gynecol Oncol. 2009; 113(2): 216-220. [cited by applicant]
Fotopoulou, “Limitations to the use of carboplatin-based therapy in advanced ovarian cancer”, EJC Suppl. 2014; 12(2): 13-16. [cited by applicant]
Antoniou et al., “Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction”, Cancer Res. 2010; 70(23): 9742-9754. [cited by applicant]
Watkins et al., “Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers”, Breast Cancer Res. 2014; 16(3): 211. [cited by applicant]
Kaelin, “The concept of synthetic lethality in the context of anticancer therapy”, Nat Rev Cancer, 2005; 5(9): 689-698. [cited by applicant]
Abkevich et al., “Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer”, Br J Cancer. 2012; 107(10): 1776-1782. [cited by applicant]
Birkbak et al., “Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents”, Cancer Discov. 2012; 2(4): 366-375. [cited by applicant]
Popova et al., “Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation”, [cited by applicant]
Mills et al., “Homologous Recombination deficiency score shows superior association with outcome compared with its individual score components in platinum-treated serous ovarian cancer”, Presented for the 47th Annual Me… [cited by applicant]
Freidlin et al., “Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients”, [cited by applicant]
Cancer Genome Atlas Research Network, “Integrated genomic analyses of ovarian carcinoma”, [cited by applicant]
Mukhopadhyay et al., “Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors”, [cited by applicant]
Aghajanian et al., “OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal… [cited by applicant]
Oza et al., “Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective”, [cited by applicant]
Markman et al., “Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design”, [cited by applicant]
Tan et al., “Long-term survival and late toxicity after chemoradiotherapy for cervical cancer—the Addenbrooke's experience”, [cited by applicant]
Bast et al., “Prevention and early detection of ovarian cancer: mission impossible?”, [cited by applicant]
Herzog et al., “SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm”, [cited by applicant]
Herzog et al., “Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper”, [cited by applicant]
Havrilesky et al., “Patient preferences in advanced or recurrent ovarian cancer”, [cited by applicant]
Schiffer et al., “Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology”, 2001; 19(5): 1519-1538. [cited by applicant]
Slichter, “Evidence-based platelet transfusion guidelines”, 2007: 172-178. [cited by applicant]
Beaumont et al., “Validation of the Functional Assessment of Cancer Therapy—Ovarian (FACT-O) Symptom Index (FOSI) in a Phase II Clinical Trial of Pertuzumab in Patients with Advanced Ovarian Cancer”, [cited by applicant]
Conner-Spady et al., “Responsiveness of the EuroQol in breast cancer patients undergoing high dose chemotherapy”, [cited by applicant]
Vardiman et al., “The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes”, [cited by applicant]
Elston, “On Fisher's Method of Combining p-Values”, [cited by applicant]
Chuang-Stein, “Some issues concerning the normalization of laboratory data based on reference ranges”, [cited by applicant]
Jaillette et al., “French Intensive Care Society, International congress—Reanimation 2016”, [cited by applicant]
Matulonis et al., “Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer”, [cited by applicant]
Hanker et al., “The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy”, [cited by applicant]
Franzese et al., “PARP inhibitors in ovarian cancer”, Cancer Treatment Reviews, vol. 73: Feb. 1-9, 2019. [cited by applicant]
Schiewer et al., “PARP-1 regulates DNA repair factor availability”, EMBO Molecular Medicine, vol. 10 (12):—Dec. 2018. [cited by applicant]
Hopkins et al., “PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow”, Molecular Cancer Research, vol. 17 (2): 409-419 Feb. 2019. [cited by applicant]
Baciarello et al., “Advancing therapies in metastatic castration-resistant prostate cancer”, Expert Opinion on Pharmacotherapy, vol. 19 (16): 1797-1804 Nov. 2, 2018. [cited by applicant]
Caffo et al., “Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?”, Frontiers in Cell and Developmental Biology, vol. 6:—Sep. 5, 2018. [cited by applicant]
Hill et al., “Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids”, Cancer Discovery, vol. 8 (11): 1404-1421 Nov. 2018. [cited by applicant]
Van Der Biessen et al., “A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer”, Investigational New Drugs,… [cited by applicant]
Ethier et al., “The role of niraparib for the treatment of ovarian cancer”, Future Oncology, vol. 14 (25): 2565-2577, Oct. 2018. [cited by applicant]
Wang et al., “Emerging therapeutic modalities of PARP inhibitors in breast cancer”, Cancer Treatment Reviews, vol. 68: 62-68, Jul. 2018. [cited by applicant]
Hoskins, “Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature”, Clinical Oncology, vol. 30 (8): 472-483 Sp. Iss. SI,… [cited by applicant]
Sharma, “Update on the Treatment of Early-Stage Triple-Negative Breast Cancer”, Current Treatment Options in Oncology, vol. 19 (5):—May 2018. [cited by applicant]
Longoria et al., “Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer”, Expert Opinion on Drug Metabolism & Toxicology, vol. 14 (5): 543-550, 2018. [cited by applicant]
Christenson et al., “PARP inhibitors for homologous recombination-deficient prostate cancer”, Expert Opinion on Emerging Drugs, vol. 23 (2): 123-133, 2018. [cited by applicant]
Moore et al., “The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities”, Gynecologic Oncology, vol. 149 (1): 214-220, Apr. 2018. [cited by applicant]
Chen et al., “The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others”, Biomedicine & Pharmacotherapy, vol. 99: 552-560, Mar. 2018. [cited by applicant]
Geenen et al., “PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer”, Clinical Pharmacokinetics, vol. 57 (4): 427-437, Apr. 2018. [cited by applicant]
Morgan et al., “PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer”, Cancer Chemotherapy and Pharmacology, vol. 81 (4): 647-658, Apr. 2018. [cited by applicant]
Schiewer et al., “DNA Damage Response in Prostate Cancer”, Cold Spring Harbor Perspectives in Medicine, vol. 9 (1):—Jan. 2019. [cited by applicant]
Moore et al., “The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer”, Cancer Chemotherapy and Pharmacology, vol. 81 (3): 497-… [cited by applicant]
Yang et al., “Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing”, Journal of Cancer, vol. 9 (2): 219-231, 2018. [cited by applicant]
Ferrara et al., “The development of PARP as a successful target for cancer therapy”, Expert Review of Anticancer Therapy, vol. 18 (2): 161-175, 2018. [cited by applicant]
Liu et al., “Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer”, Taiwanese Journal of Obstetrics & Gynecology, vol. 56 (5): 713-714, Oct. 2017. [cited by applicant]
Caruso et al., “Niraparib in ovarian cancer: results to date and clinical potential”, Therapeutic Advances in Medical Oncology, vol. 9 (9): 579-588, Sep. 2017. [cited by applicant]
Parkes et al., “Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes”, Oncologist, vol. 22 (6): 655-666, Jun. 2017. [cited by applicant]
Van Andel et al., “Human mass balance study and metabolite profiling of [cited by applicant]
Gadi et al., “Practical Approach to Triple-Negative Breast Cancer”, Journal of Oncology Practice, vol. 13 (5): 293-+ May 2017. [cited by applicant]
Del Rivero et al., “PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies”, Oncology-New York, vol. 31 (4): 265-273, Apr. 2017. [cited by applicant]
Kanjanapan et al., “Niraparib for the treatment of ovarian cancer”, Expert Opinion on Pharmacotherapy, vol. 18 (6): 631-640, Apr. 2017. [cited by applicant]
Wilson et al., “A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours”, British Journal of Cancer, vol. 116 (7): 884-892, Mar. 28, 2017. [cited by applicant]
Xiong et al., “Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems”, Medical Oncology, vol. 34 (4):—Apr. 2017. [cited by applicant]
Jdey et al., “Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors”, Clinical Cancer Research, vol. 23 (4): 1001-1011, Feb. 2017. [cited by applicant]
Brasseur et al., “Chemoresistance and targeted therapies in ovarian and endometrial cancers”, Oncotarget, vol. 8 (3): 4008-4042, Jan. 17, 2017. [cited by applicant]
Yuan et al., “PARP inhibitors as antitumor agents: a patent update (2013-2015)”, Expert Opinion on Therapeutic Patents, vol. 27 (3): 363-382, Mar. 2017. [cited by applicant]
Anderson et al., “Iodinated benzimidazole PARP radiotracer for evaluating PARP1/2 expression in vitro and in vivo”, Nuclear Medicine and Biology, vol. 43 (12): 752-758, Dec. 2016. [cited by applicant]
Konecny et al., “PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions”, British Journal of Cancer, vol. 115 (10): 1157-1173, Nov. 8, 2016. [cited by applicant]
McLachlan et al., “The current status of PARP inhibitors in ovarian cancer”, Tumori, vol. 102 (5): 433-440, Sep.-Oct. 2016. [cited by applicant]
Zhang et al., “Targeting DNA Replication Stress for Cancer Therapy”, Genes, vol. 7 (8):—Aug. 2016. [cited by applicant]
Iyevleva et al., “Cytotoxic and targeted therapy for hereditary cancers”, Hereditary Cancer in Clinical Practice, vol. 14:—Aug. 23, 2016. [cited by applicant]
Wallace, “New challenges for BRCA testing: a view from the diagnostic laboratory”, European Journal of Human Genetics, vol. 24: S10-S18 Suppl. Sep. 1, 2016. [cited by applicant]
Sahin et al., “Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches”, Expert Review of Gastroenterology & Hepatology, vol. 10 (8): 893-905, Aug. 2016. [cited by applicant]
Mazzotta et al., “Nuclear PARP1 expression and its prognostic significance in breast cancer patients”, Tumor Biology, vol. 37 (5): 6143-6153, May 2016. [cited by applicant]
Rodriguez-Freixinos et al., “Current and emerging treatment options in the management of advanced ovarian cancer”, Expert Opinion on Pharmacotherapy, vol. 17 (8): 1063-1076, 2016. [cited by applicant]
Jenner et al., “Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy”, Future Oncology, vol. 12 (12): 1439-1456, Jun. 2016. [cited by applicant]
Ledermann, “Parp inhibitors in ovarian cancer”, Annals of Oncology, vol. 27: 40-44 Suppl. Apr. 1, 2016. [cited by applicant]
Wang et al., “The BRCA1-Delta 11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin”, Cancer Research, vol. 76 (9): 2778-2790, May 1, 2016. [cited by applicant]
Drew et al., “Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and brea… [cited by applicant]
Gavande et al., “DNA repair targeted therapy: The past or future of cancer treatment?”, Pharmacology & Therapeutics, vol. 160: 65-83, Apr. 2016. [cited by applicant]
McLachlan et al., “Targeted agents and combinations in ovarian cancer: where are we now?”, Expert Review of Anticancer Therapy, vol. 16 (4): 441-454, Apr. 2, 2016. [cited by applicant]
Bai et al., “Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy”, Journal of Cellular and Molecular Medicine, vol. 20 (4): 581-593, Apr. 2016. [cited by applicant]
Liu et al., “New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors”, Current Treatment Options in Oncology, vol. 17 (3):—Mar. 2016. [cited by applicant]
Frey et al., “Targeting DNA repair: poly (ADP-ribose) polymerase inhibitors”, Translational Cancer Research, vol. 4 (1): 84-96, Feb. 2015. [cited by applicant]
Sharma et al., “BRCA-associated pancreatico-biliary neoplasms: Four cases illustrating the emerging clinical impact of genotyping”, Acta Oncologica, vol. 55 (3): 377-381, Mar. 3, 2016. [cited by applicant]
Wang et al., “An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer”, Expert Opinion on Investigational Drugs, vol. 25 (1): 15-30, Jan. 2, 2016. [cited by applicant]
McGonigle et al., “E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling”, Oncotarget, vol. 6 (38): 41307-41323, Dec. 1, 2015. [cited by applicant]
Walsh et al., “Leveraging DNA repair deficiency in gynecologic oncology”, Current Opinion in Obstetrics & Gynecology, vol. 28 (1): 24-31, Feb. 2016. [cited by applicant]
Watson et al., “Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer”, Nature Reviews Cancer, vol. 15 (12): 701-711, Dec. 2015. [cited by applicant]
Liu et al., “Targeting tumor suppressor genes for cancer therapy”, Bioessays, vol. 37 (12): 1277-1286, Dec. 2015. [cited by applicant]
Threadgill, “5-Aminoisoquinolin-1-one (5-AIQ), a Water-Soluble Inhibitor of the Poly(ADP-Ribose)Polymerases (PARPs)”, Current Medicinal Chemistry, vol. 22 (33): 3807-3829, 2015. [cited by applicant]
Musella et al., “PARP inhibition: A promising therapeutic target in ovarian cancer”, Cellular and Molecular Biology, vol. 61 (6): 44-61, 2015. [cited by applicant]
Livraghi et al., “PARP inhibitors in the management of breast cancer: current data and future prospects”, BMC Medicine, vol. 13:—Aug. 13, 2015. [cited by applicant]
Fox et al., “The sooner the better: Genetic testing following ovarian cancer diagnosis”, Gynecologic Oncology, vol. 137 (3): 423-429, Jun. 2015. [cited by applicant]
Coleman et al., “A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients wh… [cited by applicant]
Caron, “Current place of oncogenetics in the management of ovarian cancer”, Gynecologie Obstetrique & Fertilite, vol. 43 (5): 335-337, May 2015 (machine translation provided). [cited by applicant]
Jones et al., “Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination”, Journal of Medicinal Chemistry, vol. 58 (8): 3302-3314, Apr. 23, 2015. [cited by applicant]
Naipal et al., “PARP inhibitors: the journey from research hypothesis to clinical approval”, Personalized Medicine, vol. 12 (2): 139-154, 2015. [cited by applicant]
Ezzalfani et al., “The role of the expansion cohort in phase I trials in oncology: Guidelines of the phase I Hub”, Bulletin Du Cancer, vol. 102 (1): 73-82, Jan. 2015 (English language abstract). [cited by applicant]
Smith et al., “Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program”, Clinical Cancer Research, vol. 21 (4): 819-832,… [cited by applicant]
Ferraldeschi et al., “Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects”, Oncogene, vol. 34 (14): 1745-1757, Apr. 2, 2015. [cited by applicant]
Garcia et al., “A Comprehensive Approach to the Identification and Management of the BRCA Patient”, Obstetrical & Gynecological Survey, vol. 70 (2): 131-143, Feb. 2015. [cited by applicant]
Lord et al., “Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors”, Annual Review of Medicine, vol. 66: 455-470, 2015. [cited by applicant]
Sonnenblick et al., “An update on PARP inhibitors-moving to the adjuvant setting”, Nature Reviews Clinical Oncology, vol. 12 (1): 27-41, Jan. 2015. [cited by applicant]
Chao et al., “Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARP”, Molecular Cancer Research, vol. 12 (12): 1755-1766, Dec. 2014. [cited by applicant]
Fang, “Development of Synthetic Lethality Anticancer Therapeutics”, Journal of Medicinal Chemistry, vol. 57 (19): 7859-7873, Oct. 9, 2014. [cited by applicant]
Feng et al., “Molecular Pathways: Targeting ETS Gene Fusions in Cancer”, Clinical Cancer Research, vol. 20 (17): 4442-4448, Sep. 1, 2014. [cited by applicant]
Jian et al., “Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage”, Anti-Cancer Drugs, vol. 25 (8): 87… [cited by applicant]
Bridges et al., “Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells”, Oncotarget, vol. 5 (13): 5076-5086, Jul. 15, 2014. [cited by applicant]
Ferrario et al., “Advances in the approach to novel drug clinical development for breast cancer”, Expert Opinion on Drug Discovery, vol. 9 (6): 647-668, Jun. 2014. [cited by applicant]
Syrios et al., “Advanced Epithelial Ovarian Cancer: From Standard Chemotherapy to Promising Molecular Pathway Targets—Where Are we Now?”, Anticancer Research, vol. 34 (5): 2069-2077, May 2014. [cited by applicant]
Gras, “Niraparib hydrochloride. Poly [ADP-ribose] polymerase (PARP) inhibitor, Oncolytic”, Drugs of the Future, vol. 38 (10): 679-685, Oct. 2013. [cited by applicant]
Ross, M. K. et al., “Human carboxylesterases and their role in xenobiotic and endobiotic metabolism”, J Biochem Mol Toxicol, vol. 21(4):187-96, (2007). [cited by applicant]
Taketani, M. et al., Carboxylesterase in the liver and small intestine of experimental animals and human. Life Sci., vol. 81(11):924-32, (2007). [cited by applicant]
Imai T. et al., “Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine”, Drug Metab Dispos, vol. 34(10):1734-41, (2006). [cited by applicant]
Murai, J et al., Trapping of PARP1 and PARP2 by clinical PARP inhibitors, Cancer Res, vol. 72(21): 5588-5599, (2012). [cited by applicant]
Kim, G., “FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy”, Clin Cancer Res., vol. 21(19), 4257-4261… [cited by applicant]
Pal, T. P .-W., BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer, vol. 104(12), 2807-2816, (2015). [cited by applicant]
Siegel, R., “Cancer Statistics, 2014”, CA Cancer J. Clin, vol. 64, pp. 9-29, (2014). [cited by applicant]
Travis, L. B., “Risk of leukemia after platinum-based chemotherapy for ovarian cancer”, N. Engl J Med, vol. 340(5), pp. 351-357, (1999). [cited by applicant]
Zhang, S. R., “Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer”, Gynecologic Oncology, vol. 121(2), pp. 353-357, (2011). [cited by applicant]
National Cancer Institute, “Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)—Health Professional Version”, [online] (retrieved on May 19, 2019]. Retrieved from the Internet: https://www… [cited by applicant]
National Cancer Institute, A Snapshot of Ovarian Cancer, [online] (retrieved on May. 19, 2019]. Retrieved from the Internet: https://www.cancer.gov/types/ovarian?redirect=true and https://www.cancer.gov/types/ovarian/hp… [cited by applicant]
National Cancer Institute, Surveillance, Epidemiology, and End Results Program: Cancer Stat Facts: Ovarian Cancer, [online] (retrieved on May, 19, 2019]. Retrieved from the Internet: https://seer.cancer.gov/statfacts/ht… [cited by applicant]
American Cancer Society, Inc. Cancer Facts & Figures, p. 18, (2016), [online] (retrieved on May 19, 2019]. Retrieved from the Internet: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/… [cited by applicant]
U.S. Food & Drug Administration, Drug Approval Package: Zejula (niraparib), Company: TESARO, Inc., Application No. 208447Orig1s000, Approval Date: Mar. 27, 2017, [cited by applicant]
U.S. Food & Drug Administration, Drug Approval Package: Zejula (niraparib), Company: TESARO, Inc., Application No. 208447Orig1s000, Approval Date: Mar. 27, 2017, [cited by applicant]
U.S. Food & Drug Administration, Drug Approval Package: Zejula (niraparib), Company: TESARO, Inc., Application No. 208447Orig1s000, Approval Date: Mar. 27, 2017, [cited by applicant]
U.S. Food & Drug Administration, Drug Approval Package: Zejula (niraparib), Company: TESARO, Inc., Application No. 208447Orig1s000, Approval Date: Mar. 27, 2017, [cited by applicant]
U.S. Food & Drug Administration, Drug Approval Package: Zejula (niraparib), Company: TESARO, Inc., Application No. 208447Orig1s000, Approval Date: Mar. 27, 2017, [cited by applicant]
U.S. Food & Drug Administration, Drug Approval Package: Zejula (niraparib), Company: TESARO, Inc., Application No. 208447Orig1s000, Approval Date: Mar. 27, 2017, [cited by applicant]
U.S. Food & Drug Administration, Drug Approval Package: Zejula (niraparib), Company: TESARO, Inc., Application No. 208447Orig1s000, Approval Date: Mar. 27, 2017, [cited by applicant]
U.S. Food & Drug Administration, Drug Approval Package: Zejula (niraparib), Company: TESARO, Inc., Application No. 208447Orig1s000, Approval Date: Mar. 27, 2017, [cited by applicant]
U.S. Food & Drug Administration, Drug Approval Package: Zejula (niraparib), Company: TESARO, Inc., Application No. 208447Orig1s000, Approval Date: Mar. 27, 2017, [cited by applicant]
U.S. Food & Drug Administration, Highlights of Prescribing Information, ZEJULAT™ (niraparib) capsules, for oral use, Initial U.S. Approval: 2017, [online] (retrieved on May 19, 2019]. Retrieved from the Internet: https:… [cited by applicant]
Pazdur, Richard, Letter from U.S. Department of Health and Human Services, U.S. Food and Drug Administration, NDA 208447, to Charles A. Miller, Vice President, Regulatory Affairs, 1000 Winter Street, Suite 3300, Waltham… [cited by applicant]
Bakir et al., “The molecular genetics of hereditary and sporadic ovarian cancer: implications for the future,” British Medical Bulletin, 2014, 13 pages 112:57-69; doi: 10.1093/bmb/ldu034. [cited by applicant]
Kim et al., “Molecular Cell Activation of PARP-1 by snoRNAs Controls Ribosome Biogenesis and Cell Growth via the RNA Helicase DDX21” 31 pages, Sep. 19, 2019 © 2019 Elsevier Inc. https://doi.org/10.1016/j.molcel.2019.06.… [cited by applicant]
Scott et al., “Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development,” 11 pages, American Society of Clinical Oncology, Journal of Clinical Oncology, Biology of Neoplasia, vol. 33, No. 12, Apr.… [cited by applicant]
Mukhopadhyay et al., “Clinicopathological Features of Homologous Recombination—Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival”, [cited by applicant]
European Search Report dated Feb. 14, 2020 for EP Application No. 17821262.7. [cited by applicant]
Zhang et al., “A genomic instability score in discriminating nonequivalent outcomes of BRCA1/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapy.” [cited by applicant]
Berge et al., “Pharmaceutical salts,” J. Pharmaceutical Sciences, 1977, 66:1-19. [cited by applicant]
Bookman et al., “Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup,” J Clin Oncol., 2009, 27(9):1419-1425. [cited by applicant]
Du Bois et al., “2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004),” Ann Oncol., 20… [cited by applicant]
Eisenhauer, et al., “New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1.),” Eur. J. of Cancer, 45: 228-247 (2009). [cited by applicant]
Mutch et al., “2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer,” Gynecol Oncol., 2014, 133(3):401-404. [cited by applicant]
Ozols et al., “Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study,” J Clin Oncol., 2003,… [cited by applicant]
Pfisterer et al., “Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG,” J Clin Oncol… [cited by applicant]
Rustin et al., “Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG),” Int J Gynecol Cancer, 2011, 21:419-42… [cited by applicant]